<DOC>
	<DOCNO>NCT01925794</DOCNO>
	<brief_summary>This prospective , multi-center , non-randomized , single arm clinical trial conduct 40 site United States Outside United States ( OUS ) . This study enroll patient symptomatic ischemic heart disease due single de novo lesion contain within native coronary artery reference vessel diameter 2.5 mm 4.0 mm lesion length ≤ 24 mm amenable percutaneous coronary intervention ( PCI ) stent deployment . All patient follow 30 day , 6 month , 9 month , 1 year annually 5 year post index stenting procedure .</brief_summary>
	<brief_title>The PzF Shield Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>General 1 . Patient &gt; /= 18 year old . 2 . Eligible percutaneous coronary intervention ( PCI ) . 3 . Patient understands nature procedure provide write informed consent prior catheterization procedure . 4 . Patient willing comply specify followup evaluation contact telephone . 5 . Acceptable candidate coronary artery bypass graft ( CABG ) surgery . 6 . Stable angina pectoris ( Canadian Cardiovascular Society ( CCS ) 1 , 2 , 3 4 ) unstable angina pectoris ( Braunwald Class 13 , BC ) positive functional ischemia study ( e.g. , ETT , SPECT , Stress echocardiography Cardiac CT ) . 7 . Male nonpregnant female patient ( Note : female child bear potential must negative pregnancy test prior enrollment study ) . Angiographic Inclusion Criteria 1 . Patient indicate elective stenting single stenotic lesion native coronary artery . 2 . Reference vessel &gt; /= 2.5 mm &lt; /= 4.0 mm diameter visual estimate . 3 . Target lesion &lt; /= 24 mm length visual estimate ( intention cover whole lesion one stent adequate length ) . 4 . Protected leave main lesion &gt; 50 % stenosis . 5 . Target lesion stenosis &gt; /= 70 % &lt; 100 % visual estimate . 6 . Target lesion stenosis &lt; 70 % meet physiological criterion revascularization ( i.e . positive FFR ) . General 1 . Currently enrol another investigational device drug trial complete primary endpoint clinically interfere current study endpoint . 2 . Previously enrol another stent trial within prior 2 year . 3 . ANY plan elective surgery percutaneous intervention within subsequent 3 month . 4 . A previous coronary interventional procedure kind within 30 day prior procedure . 5 . The patient require staged procedure either target nontarget vessel within 9 month postprocedure . 6 . The target lesion require treatment device PTCA prior stent placement ( , limit , directional coronary atherectomy , excimer laser , rotational atherectomy , etc. ) . 7 . Previous drug elute stent ( DES ) deployment anywhere target vessel . 8 . Any previous stent placement within 15 mm ( proximal distal ) target lesion . 9 . Comorbid condition ( ) could limit patient 's ability participate trial comply followup requirement , impact scientific integrity trial . 10 . Concurrent medical condition life expectancy le 12 month . 11 . Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % within 12 month prior enrollment . 12 . Patients diagnosis MI within 72 hour ( i.e . CKMB must return normal prior enrollment ) suspect acute MI time enrollment 13 . Previous brachytherapy target vessel . 14 . History cerebrovascular accident transient ischemic attack last 6 month . 15 . Leukopenia ( leukocytes &lt; 3.5 x 10 ( 9 ) / liter ) . 16 . Neutropenia ( Absolute Neutrophil Count &lt; 1000/mm3 ) &lt; /= 3 day prior enrollment . 17 . Thrombocytopenia ( platelet &lt; 100,000/mm3 ) preprocedure . 18 . Active peptic ulcer active GI bleeding . 19 . History bleed diathesis coagulopathy inability accept blood transfusion . 20 . Known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , L605 Cobalt chromium alloy sensitivity contrast medium , adequately premedicated . 21 . Serum creatinine level &gt; 2.0 mg/dl within 7 day prior index procedure . 22 . Patients unable tolerate dual antiplatelets therapy ( DAPT ) one month post procedure . Angiographic Exclusion Criteria 1 . Unprotected leave main coronary artery disease ( obstruction great 50 % leave main coronary artery protect least one nonobstructed bypass graft LAD Circumflex artery branch thereof ) . 2 . Target vessel lesion great 50 % diameter stenosis outside range 5 mm proximal distal target lesion base visual estimate online QCA . 3 . Target lesion ( vessel ) exhibit intraluminal thrombus ( occupy &gt; 50 % true lumen diameter ) time . 4 . Lesion location aortoostial within 5 mm origin leave anterior descending ( LAD ) leave circumflex ( LCX ) . 5 . Target lesion side branch &gt; 2.0mm diameter . 6 . Target vessel excessively tortuous ( two bend &gt; 90˚ reach target lesion ) . 7 . Target lesion severely calcify . 8 . TIMI flow 0 1 9 . Target lesion bypass graft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stent , Coronary Arteries Early healing</keyword>
</DOC>